Qube Research & Technologies (QRT)
DMAC icon

Qube Research & Technologies (QRT)’s DiaMedica Therapeutics DMAC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,881
Closed -$73.7K – 3600
2026
Q1 		$73.7K Buy
+10,881
New +$86.2K ﹤0.01% 3115
2025
Q4 		– Sell
-39,549
Closed -$272K – 3755
2025
Q3 		$272K Buy
+39,549
New +$215K ﹤0.01% 2876
2025
Q2 		– Sell
-36,929
Closed -$140K – 3631
2025
Q1 		$140K Sell
36,929
-57,840
-61% -$331K ﹤0.01% 2946
2024
Q4 		$515K Buy
94,769
+42,680
+82% +$201K ﹤0.01% 2462
2024
Q3 		$218K Buy
+52,089
New +$192K ﹤0.01% 2547
2021
Q1 		– Sell
-18,785
Closed -$190K – 2011
2020
Q4 		$190K Sell
18,785
-12,449
-40% -$68.1K ﹤0.01% 1546
2020
Q3 		$132K Buy
+31,234
New +$165K ﹤0.01% 1463

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Qube Research & Technologies (QRT)'s DMAC Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 10,881 shares — an estimated $73.7K sold.

Qube Research & Technologies (QRT) first reported a position in DMAC in Q3 2020 and held it in 7 quarters. The position peaked at $515K in Q4 2024. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 10,881 DiaMedica Therapeutics shares in Q2 2026, an estimated $73.7K.
  • Qube Research & Technologies (QRT) first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 7 quarters.
  • Qube Research & Technologies (QRT)'s DiaMedica Therapeutics position peaked at $515K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.